Resumen de Seguridad del tratamiento combinado de la hepatitis crónica por el virus de la hepatitis C con ribavirina y peginterferón alfa
Neus Sunyer Esquerrà, Isabel De La Paz Cañizares, Blanca Martínez Sánchez, María Teresa Butiñà Agustí
The objective of the study is to analyse adverse reactions to the treatment of chronic hepatitis virus C with Ribavirin and peginterferon alpha and the causes of suspension, as well as the required support treatment. Retrospective, descriptive study. 53 Patients were included, the treatment was interrupted in 13 cases, the majority due to a lack of virological response (n = 9). Of these 9 patients, three were treated with peginterferon alpha-2a and six with 2 b. 90% Of patients presented adverse reactions, 6% required dose adjustment and 4% needed suspension of the treatment. Despite being a treatment with high adverse reactions, the major cause of abandonment of the treatment is the lack of response. The pharmacist has an important role in the adherence and management of adverse reactions to help achieve the goal of treatmen
